Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-01-2017 | Letter to the Editor

¹⁷⁷Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response

Authors: Kambiz Rahbar, Martin Bögemann, Hojjat Ahmadzadehfar

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2017

Excerpt

Dear Editor, …

Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A, et al. ¹⁷⁷Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol Imaging. 2016. doi:10.1007/s00259-016-3481-7.

Ahmadzadehfar H, Rahbar K, Kurpig S, Bogemann M, Claesener M, Eppard E, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015. doi:10.1186/s13550-015-0114-2.

Ahmadzadehfar H, Eppard E, Kurpig S, Fimmers R, Yordanova A, Schlenkhoff CD, et al. Therapeutic response and side effects of repeated radioligand therapy with ¹⁷⁷Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016. doi:10.18632/oncotarget.7245.PubMedPubMedCentral

Kratochwil C, Giesel FL, Stefanova M, Benesova M, Bronzel M, Afshar-Oromieh A, Mier W, Eder M, Kopka K, Haberkorn U. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617. J Nucl Med. 2016.

Rahbar K, Bode A, Weckesser M, Avramovic N, Claesener M, Stegger L, et al. Radioligand therapy with ¹⁷⁷Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration-resistant prostate cancer. Clin Nucl Med. 2016. doi:10.1097/RLU.0000000000001240.

Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, Claesener M, Ahmadzadehfar H. Response and tolerability of a single dose of ¹⁷⁷Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis. J Nucl Med. 2016.

Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Prostate cancer clinical trials working group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol. 2008. doi:10.1200/JCO.2007.12.4487.

Lapa C, Werner RA, Bluemel C, Lueckerath K, Muegge DO, Strate A, et al. Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy. EJNMMI Res. 2014. doi:10.1186/s13550-014-0074-y.

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009. doi:10.2967/jnumed.108.057307.

Title: 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
Authors: Kambiz Rahbar
Martin Bögemann
Hojjat Ahmadzadehfar
Publication date: 01-01-2017
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3530-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

¹⁷⁷Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2017

Editorial: Listen to your belly, fat is not your foe!

Prediction of coronary artery calcium progression by FDG uptake of large arteries in asymptomatic individuals

The value of 18F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in oesophageal adenocarcinoma

Reply

Reply to Rahbar K et al.

Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT